Cafepharma Today

May 30 2025 - #ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer
#ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer
Roche links BTK inhibitor to low relapse rate across 96-week multiple sclerosis trial
Mixed COPD results for Regeneron, Sanofi drug cloud approval chances
Illumina introduces a new AI algorithm PromoterAI
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Analyst says Immunogen's T-DM1 will become standard breast cancer treatment; rates stock 'Buy'
Yahoo/AP
Wednesday, July 6, 2011 - 8:47am
tags:
Immunogen, T-DM1, breast cancer
The Short Case for Zalicus: Not Worth Its Market Cap
Seeking Alpha
Wednesday, July 6, 2011 - 8:21am
tags:
Zalicus, Exalgo, Synavive
Alere Makes Unsolicited $369 Million Offer for Axis-Shield
Bloomberg
Wednesday, July 6, 2011 - 8:18am
tags:
Alere, M&A, Axis-Shield, Inverness Medical
AstraZeneca unit loses patent rights
FT.com
Wednesday, July 6, 2011 - 8:17am
tags:
AstraZeneca, patents, Roche, MedImmune, ranibizumab, Novartis
Gentium Announces NDA Submission for Defibrotide
Yahoo
Wednesday, July 6, 2011 - 8:15am
tags:
Gentium, NDA, Defibrotide, FDA, veno-occlusive disease
Potential Dividend Growth for 5 Large Pharmaceutical Companies: 2011 to 2015
Seeking Alpha
Tuesday, July 5, 2011 - 9:58pm
tags:
dividends, Bristol-Myers Squibb, JNJ, Eli Lilly, Merck, Pfizer
U.S. Medicare proposes change in anemia drug usage
Reuters
Tuesday, July 5, 2011 - 7:02pm
tags:
Medicare, anemia, Epogen, Amgen
Russia targets Novartis, Teva
Investors.com
Tuesday, July 5, 2011 - 7:00pm
tags:
Novartis, Russia, Teva Pharmaceuticals
FDA grants "orphan drug" status to CytRx's experimental cancer drug
Yahoo/AP
Tuesday, July 5, 2011 - 4:44pm
tags:
orphan drugs, FDA, CytRx, INNO-206, cancer
Xarelto Approved, But No Fireworks Yet
Motley Fool
Tuesday, July 5, 2011 - 4:42pm
tags:
blood thinners, Xarelto, Bayer, JNJ
pSivida on the Cusp of Big Breakthrough
Seeking Alpha
Tuesday, July 5, 2011 - 4:39pm
tags:
Pfizer, pSivida, diabetic macular edema, injectables, age-related macular degeneration, Durasert, glaucoma
Eli Lilly Reaffirms Commitment to Innovation but Needs to Deliver
Seeking Alpha
Tuesday, July 5, 2011 - 4:37pm
tags:
innovation, Eli Lilly, Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, GSK, JNJ, Merck, Novartis, Pfizer, Roche, Sanofi
Painkillers linked to atrial fibrillation in Danish study
Pharma Times, UK
Tuesday, July 5, 2011 - 11:52am
tags:
painkillers, atrial fibrillation, NSAIDs, COX-2 inhibitors
E-Prescribing & Handwritten Error Rates Are Similar
Pharmalot
Tuesday, July 5, 2011 - 11:51am
tags:
e-prescribing, physicians
Harvard docs punished for undisclosed pharma ties
Fierce Pharma
Tuesday, July 5, 2011 - 11:33am
tags:
Harvard, physician payments, physicians
Jazz Reaches New 52-Week High
TheStreet.com
Tuesday, July 5, 2011 - 11:32am
tags:
Jazz Pharmaceuticals
Adventrx's Exelbine Could Be Available This Year
Seeking Alpha
Tuesday, July 5, 2011 - 11:30am
tags:
Exelbine, Adventrx, Small-Cell Lung Cancer
Seattle Genetics, on the Verge of Going Commercial, Seeks to Keep Its Scientific Soul
Motley Fool
Tuesday, July 5, 2011 - 11:29am
tags:
Seattle Genetics
Eight years in the making, N.J.-based Merck developing new kind of insomnia drug
Newark Star-Ledger, NJ
Tuesday, July 5, 2011 - 11:28am
tags:
Merck, insomnia
Merck commits to increased transparency on study protocols
Pharma Times, UK
Tuesday, July 5, 2011 - 11:21am
tags:
Merck, transparency, clinical trials

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.